Once‐daily administration of trospium chloride extended release provides 24‐hr coverage of nocturnal and diurnal symptoms of overactive bladder: An integrated analysis of two phase III trials
暂无分享,去创建一个
P. Ellsworth | David A Ginsberg | Michael G Oefelein | Pamela I Ellsworth | Michael G. Oefelein | D. Ginsberg
[1] Sum Lam,et al. Pharmacologic management of overactive bladder , 2007, Clinical interventions in aging.
[2] J. J. de la Rosette,et al. Muscarinic receptor antagonists for overactive bladder treatment: does one fit all? , 2009, Current opinion in urology.
[3] R. Asplund. Nocturia in relation to sleep, health, and medical treatment in the elderly , 2005, BJU international.
[4] R G Marks,et al. Nocturia: A Risk Factor for Falls in the Elderly , 1992, Journal of the American Geriatrics Society.
[5] R. Dmochowski,et al. Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. , 2008, Urology.
[6] C. Tannenbaum,et al. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence , 2009, Current opinion in urology.
[7] W. Stewart,et al. Prevalence and burden of overactive bladder in the United States , 2003, World Journal of Urology.
[8] S. Colman,et al. A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. , 2005, The Journal of urology.
[9] K. Coyne,et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well‐being in men and women: results from the EPIC study , 2008, BJU international.
[10] P. Abrams,et al. Understanding the elements of overactive bladder: questions raised by the EPIC study , 2008, BJU international.
[11] R. Dmochowski,et al. Trospium chloride once‐daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials , 2009, International journal of clinical practice.
[12] R. Dmochowski,et al. Extended-release trospium chloride improves quality of life in overactive bladder. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[13] J. Donovan,et al. Urinary symptoms and incontinence in women: relationships between occurrence, age, and perceived impact. , 1999, The British journal of general practice : the journal of the Royal College of General Practitioners.
[14] T. Wagner,et al. Health-related consequences of overactive bladder. , 2002, The American journal of managed care.
[15] P. Abrams,et al. Muscarinic receptor antagonists for overactive bladder , 2007, BJU international.
[16] R. Scarpa. Lower Urinary Tract Symptoms: What Are the Implications for the Patients? , 2001, European Urology.
[17] J. J. de la Rosette,et al. Role of muscarinic receptor antagonists in urgency and nocturia , 2005, BJU international.
[18] N. Silver,et al. Pharmacokinetics of Once‐Daily Trospium Chloride 60 mg Extended Release and Twice‐Daily Trospium Chloride 20 mg in Healthy Adults , 2010, Journal of clinical pharmacology.
[19] R. Lipton,et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. , 2001, Urology.
[20] P. Sand,et al. Nocturia: Etiology, diagnosis, and treatment , 2008, Neurourology and urodynamics.
[21] C. Thompson,et al. The prevalence of nocturia and its effect on health‐related quality of life and sleep in a community sample in the USA , 2003, BJU international.
[22] R. Dmochowski,et al. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. , 2007, The Journal of urology.
[23] A. Mitchell,et al. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. , 2002, JAMA.
[24] S. Madersbacher,et al. Nocturia is an age‐independent risk factor for hip‐fractures in men , 2009, Neurourology and urodynamics.
[25] Z. Gabriel,et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. , 2008, European urology.
[26] E. Vittinghoff,et al. Urinary Incontinence: Does it Increase Risk for Falls and Fractures? , 2000, Journal of the American Geriatrics Society.
[27] Magnus Fall,et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. , 2003, Urology.